Advertisement

Topics

Embrella Cardiovascular, Inc. Company Profile

18:30 EST 20th November 2018 | BioPortfolio

Embrella Cardiovascular™, Inc., is dedicated to creating a new standard-of-care for cerebral embolic protection during cardiovascular procedures. Embrella's Embolic Deflector®, an aortic embolic protection device which acts as a protective shield to reduce the incidence of embolization to the brain, has been granted CE Mark approval. Embrella is a private, venture backed medical device company whose investors include BioStar Ventures, MedFocus Fund, Hatteras Venture Partners and Edwards Lifesciences Corporation.


News Articles [558 Associated News Articles listed on BioPortfolio]

Traditional Chinese medicine is widely used for cardiovascular disease

(Cardiovascular Innovations and Applications) In this Letter to the Editor, the authors comment on a review article which assesses the efficacy and safety of TCM for cardiovascular disease, as well as...

Use of bivalirudin for anticoagulation in interventional cardiovascular procedures

(Cardiovascular Innovations and Applications) In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp. 149-162(14); DOI: 10.15212/CVIA.2017.0045 Zhen Ge, Jaya ...

Multivitamins Don't Appear to Boost Cardiovascular Health

Taking a daily multivitamin is not associated with lower risk for adverse cardiovascular outcomes, according to a meta-analysis in Circulation: Cardiovascular Quality and Outcomes...

[Articles] SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust b...

Researchers reveal link between autoimmune and cardiovascular disease in mice

People with autoimmune diseases such as psoriasis, lupus and rheumatoid arthritis are at high risk of developing cardiovascular disease, even though none of these conditions seem to target the cardiov...

Omega-3 fats Supplements Effect on Cardiovascular Health: EPA and DHA has little or no effect on Mortality or Cardiovascular Health 

Omega-3 fats Supplements Effect on Cardiovascular Health: EPA and DHA has little or no effect on Mortality or Cardiovascular Health Reporter: Aviva Lev-Ari, PhD, RN   Cochrane Database Syst Rev....

[Articles] Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor ag...

Albiglutide Beats Placebo for Cardiovascular Events in T2DM

THURSDAY, Oct. 4, 2018 -- For patients with type 2 diabetes and existing cardiovascular disease, albiglutide results in fewer cardiovascular events, according to a study published online Oct. 2 in The...

PubMed Articles [1624 Associated PubMed Articles listed on BioPortfolio]

Association of Change in Cardiovascular Risk Factors With Incident Cardiovascular Events.

There is consistent evidence of the association between ideal cardiovascular health and lower incident cardiovascular disease (CVD); however, most studies used a single measure of cardiovascular healt...

Circulating Wnt inhibitory factor 1 levels are associated with development of cardiovascular disease.

Wnt signaling is involved in atherosclerotic plaque formation directly and indirectly by modulating cardiovascular risk factors. We investigated whether circulating concentrations of Wnt inhibitors ar...

Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovas...

3D bioprinting for cardiovascular regeneration and pharmacology.

Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Compared to traditional therapeutic strategies, three-dimensional (3D) bioprinting is one of the most advanced techn...

Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: a meta-analysis of cardiovascular outcomes trials.

To show long-term cardiovascular safety of the GLP-1 receptor agonists for diabetes patients with cardiovascular risk.

Clinical Trials [2919 Associated Clinical Trials listed on BioPortfolio]

Cardiovascular Disease Cohort in Guangdong Province

Patients with cardiovascular diseases from Guangdong province will be recruited and followed up for at least 4 years to evaluate the risk factors for cardiovascular-related mortality and d...

Factors Influencing Cardiovascular Prognosis

The purpose of this study is to identify risks for cardiovascular events in a follow up period of 10 years.

Work Organization and Cardiovascular Disease

To determine the combined effects of job strain and social isolation on cardiovascular morbidity and mortality.

Role of Vitamin D in Secondary Prevention of Cardiovascular Events

The purpose of this study is to determine if Vitamin D supplementation helps prevent recurrent cardiovascular events, such as heart attack or stroke, in patients who have already experienc...

Partnership Programs for Reducing Cardiovascular Disparities in Native Hawaiians

The purpose of this study is to improve cardiovascular disease (CVD) outcomes in racial and ethnic minorities in Hawaii.

Companies [613 Associated Companies listed on BioPortfolio]

Embrella Cardiovascular, Inc.

Embrella Cardiovascular™, Inc., is dedicated to creating a new standard-of-care for cerebral embolic protection during cardiovascular procedures. Embrella's Embolic Deflector...

Cardiovascular Consultants, Ltd.

Cardiovascular Consultants, Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate ...

Cardiovascular Consultants Ltd.

Cardiovascular Consultants Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate c...

Cardiovascular Consultants

Cardiovascular Consultants is a medical practice that specializes exclusively in the diagnosis, treatment, prevention and management of cardiovascular diseases and conditions. What makes us different ...

CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company cu...

More Information about "Embrella Cardiovascular, Inc." on BioPortfolio

We have published hundreds of Embrella Cardiovascular, Inc. news stories on BioPortfolio along with dozens of Embrella Cardiovascular, Inc. Clinical Trials and PubMed Articles about Embrella Cardiovascular, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Embrella Cardiovascular, Inc. Companies in our database. You can also find out about relevant Embrella Cardiovascular, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Corporate Database Quicklinks



Searches Linking to this Company Record